Brind.

Leerink and Stifel analysts commented on efficacy data following the separation of Myqorzo from the Camzyos market.

1 report, 1 independent Updated Aug 31

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Bristol-Myers Squibb Cytokinetics

Keep exploring

The entities involved

Bristol-Myers Squibb
American pharmaceutical company
- Bristol-Myers Squibb is developing innovative treatments and supporting Cyprus' national effort in haematology.Mon 13:45
- FDA gave tentative approval to Lupin for an alternative formulation of a Bristol-Myers Squibb drug, which Lupin plans to manufacture in Somerset.Mon 09:09
Cytokinetics
company in South San Francisco, United States
- Price targets for UDR were adjusted by Cantor Fitzgerald, Scotiabank, and Royal Bank of Canada on May 26, 2026.Sun 00:44
- The FDA has approved a drug developed by Cytokinetics for its intended use as a treatment.Wed 15:26

Related events

Product Myqorzo received FDA approval.Wed 15:26
Report covers clinical trials for Mycosis Fungoides involving Bristol-Myers Squibb, Johnson & Johnson, Merck, and Novartis.Jun 8
The FDA approved Zenbexus oral therapy for multiple myeloma, coinciding with disclosures regarding insider buying and selling transactions.Aug 30

Coverage

Newest first; wire copies grouped

Aug 31biopharmadive.com